RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin

Jung Won Chun 1, Boyoung Lee 1, Weon Seo Park 2, Nayoung Han 1,2, Eun Kyung Hong 1,2, Eun Young Park 3, Sung Sik Han 1, Sang-Jae Park 1, Tae Hyun Kim 1, Woo Jin Lee 1 and Sang Myung Woo 1,*

1 Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang-Si 10408, Gyeonggi-Do, Korea; deli4927@snu.ac.kr (J.W.C.); bylee11050724@gmail.com (B.L.); hanny@ncc.re.kr (N.H.); hongek@ncc.re.kr (E.K.H.); sshan@ncc.re.kr (S.S.H.); spark@ncc.re.kr (S.-I.P.); k2onco@ncc.re.kr (T.H.K.); lwj@ncc.re.kr (W.J.L.)
2 Department of Pathology, National Cancer Center, Goyang-Si 10408, Gyeonggi-Do, Korea; thymus@ncc.re.kr
3 Biometrics Research Branch, Research Institute, National Cancer Center, Goyang-Si 10408, Gyeonggi-Do, Korea; 13140@ncc.re.kr
* Correspondence: wsm@ncc.re.kr; Tel.: +82-31-920-1733; Fax: +82-31-920-2798

Abstract: The combination of gemcitabine plus cisplatin (GP) is regarded as a first-line treatment for patients with unresectable or recurrent biliary tract cancer (BTC). Several proteins including human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (DCK), cytidine deaminase (CDA), and ribonucleotide reductase subunit 1 (RRM1) are known to be involved in gemcitabine uptake and metabolism. This study was aimed to identify the predictive and prognostic values of these biomarkers in patients who treated with GP for advanced BTC. Tumor samples were obtained from 34 patients with unresectable or recurrent BTC who were treated with GP between August 2015 and February 2018. Intratumoral expression of hENT1, DCK, CDA and RRM1 was determined by immunohistochemistry and analyzed for association with chemotherapy response, progression-free survival (PFS) and overall survival (OS). Median OS was significantly longer in the RRM1-negative group than in the RRM1-positive (9.9 months vs. 5.9 months, p = 0.037). Multivariate adjustment analyses also demonstrated RRM1 expression as an independent prognostic factor for OS in patients treated with GP chemotherapy. Increased intratumoral expression of RRM1 on immunohistochemical staining may be a biomarker predicting poor survival in patients with GP chemotherapy for advanced BTC. Large-scale well-predefined prospective research is needed to validate the utility of biomarkers in clinical practice.

Keywords: biliary tract neoplasms; cisplatin; gemcitabine; ribonucleotide reductases

1. Introduction

Biliary tract cancers (BTCs) are uncommon malignant neoplasms of the gastrointestinal tract, which consist of a group of heterogeneous tumors including gallbladder (GB) cancer, cholangiocarcinoma (CCA) of the extra- and intra-hepatic bile ducts, and the ampulla of Vater [1,2]. Most patients with BTC have advanced, unresectable cancer at an initial diagnosis, and have poor survival outcomes with a median overall survival (OS) of less than 1 year [2]. In patients with unresectable BTC, palliative systemic chemotherapy is the mainstay treatment strategy [3]. Although several studies have reported that gemcitabine and gemcitabine-based chemotherapy regimens are effective in patients with advanced BTC, the combination of gemcitabine and cisplatin (GP) is now accepted as the standard first-line chemotherapy in these patients [4–7].

Predicting patient response to chemotherapeutic agents would be useful in selecting appropriate patients for chemotherapy and in predicting survival outcomes. Several transporters, including human equilibrative nucleoside transporter-1 (hENT1) and human...
concentrative nucleoside transporters (hCNT), and several enzymes, such as deoxycytidine kinase (DCK), deoxycytidine deaminase (CDA), and ribonucleotide reductase M1 (RRM1), were found to be involved in gemcitabine uptake and metabolism [8,9]. Further, these proteins have been suggested as predictors for the efficacy of gemcitabine treatment and prognostic biomarkers in several cancer cell lines and specimens [10–13].

In BTCs, expression levels of hENT1 and RRM1 have also been associated with gemcitabine sensitivity [14–16]. A recent systematic review and meta-analysis, which evaluated the prognostic value of 26 immunohistochemical biomarkers in 1348 patients with BTC, suggested that hENT1 may be a promising biomarker for patient response to gemcitabine-based chemotherapy [17]. The study mainly discussed the results of hENT1, RRM1, and Excision Repair Cross-Complementation 1, which were frequently evaluated biomarkers. However, the prognostic value of the two other biomarkers except hENT1 showed unclear results, and the remaining 23 biomarkers including CDA and DCK were not discussed in detail due to the limited number of studies.

Our group has previously reported the predictive and prognostic values of CDA and DCK in BTC. Although the polymorphism of CDA was associated with tumor response in unresectable, metastatic BTC patients treated with GP chemotherapy, immunohistochemical evaluation was not performed [18]. Further, DCK positivity was significantly associated with longer recurrence-free survival in resected BTC with postoperative gemcitabine chemotherapy [19]. However, most patients with BTC are not indicated for curative intent surgery at initial diagnosis, and GP chemotherapy is the most effective regimen for advanced BTC. Therefore, in this study, we aimed to evaluate the predictive and prognostic value of key molecules (hENT1, DCK, CDA, and RRM1) in gemcitabine metabolism by analyzing the intratumoral expression in tumor samples and clarify which biomarker is the most reliable for patients treated with GP chemotherapy for unresectable, metastatic and recurrent BTC.

2. Materials and Methods
2.1. Patients and Data Collection

From August 2015 through February 2018, consecutive patients with advanced unresectable or recurrent BTC who received GP chemotherapy were prospectively enrolled in this study. BTC is comprised of GB cancer, intrahepatic and extrahepatic CCA. The study protocol was approved by the Institutional Review Board of the National Cancer Center, Korea (IRB No. NCC2015-0113) and was conducted in accordance with the provisions of the Declaration of Helsinki. All participants provided written informed consent before recruitment.

The combination chemotherapy regimen consisted of cisplatin 25 mg/m² and gemcitabine 1000 mg/m² administered intravenously on days 1 and 8 every 3 weeks. Patients were included if they had at Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 and adequate organ function, including an absolute neutrophil count ≥ 1500/mm³; a platelet count ≥ 100,000/mm³; serum creatinine ≤ 1.5 X the upper limit of normal; total bilirubin ≤ 1.5 mg/dL; and either AST or ALT 2× the upper limit of normal at baseline. Patients were excluded if they had received prior anticancer therapy for the current malignancy or if their tumor type was other than adenocarcinoma.

Tumors were evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) every three cycles during chemotherapy or earlier if clinically indicated using appropriate tumor imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI). The best overall response for each patient was recorded. The decision to discontinue treatment was based on disease progression, the patient’s choice, the clinician’s judgment, or unacceptable treatment-related adverse events (AEs). Progression-free survival (PFS) was defined as the time from the date of subject enrollment until tumor progression on imaging or death, and OS was defined as the time from subject enrollment to the date of death. All AEs were graded according to the National Cancer Institute’s Common Toxicity Criteria (version 4.0).
2.2. Preparation and Immunostaining of Specimens

In patients with advanced unresectable BTC, tumor biopsy specimens for pathologic diagnosis were obtained by experienced radiologists. Needle biopsies were performed using a freehand technique under real-time ultrasound guidance, targeting primary or metastatic tumor tissue. Usually, two biopsy samples were obtained from each tumor mass using an 18-gauge biopsy device under ultrasound guidance. In recurrent cases after surgery, primary resection specimens were used for the evaluation of marker expression. All specimens were independently examined by two pathologists (W.S.P. and E.K.H). Tumors were classified as well-differentiated, moderately differentiated, or poorly differentiated adenocarcinomas, based on predominant pathological grading. Hematoxylin and eosin-stained slides containing specimens from each BTC sample were reviewed, and a representative tumor region and the corresponding formalin-fixed paraffin-embedded tissue block were selected for immunohistochemistry (IHC). One to three paraffin-embedded blocks (median, two blocks) of each specimen were evaluated by IHC. Three serial 3-µm sections were cut and prepared from each block: one for hematoxylin-eosin staining; one for immunostaining with the indicated primary antibodies against proteins associated with gemcitabine transport and metabolism; and one as a negative control. Primary antibodies included rabbit polyclonal antibodies to human CDA (catalog number: 48-962, ProSci, Inc., Poway, CA, USA), human DCK (catalog number: LS-B1825, LifeSpan Bioscience, Inc., Seattle, WA, USA), human hENT1 (catalog number: 11337-1-AP, ProteinTech Group, Inc., Chicago, IL, USA), and human RRM1 (catalog number: 10526-1-AP, ProteinTech Group, Inc.) [16].

Immunoreactivities of proteins were assessed by two experienced pancreaticobiliary pathologists. Protein expression of tumor cells was scored by immunostaining intensities as follows: grade 0, not stained; grade 1, faint positive; grade 2, weak to moderate positive; grade 3, strong positive. The staining intensity of tumor was determined by the most intense staining tumor cell. Discrepancies between the two pathologists were settled by the use of a multiheaded microscope to arrive at a final consensus.

2.3. Statistical Analysis

The primary outcomes were OS and PFS. Median follow-up was calculated using the reverse Kaplan–Meier method [20]. Survival was estimated using the Kaplan–Meier method and compared by log-rank tests. The associations of clinicopathological factors with OS were analyzed using Cox proportional-hazards regression models. Factors with p-values < 0.1 on univariate analysis were included in the multivariate regression model, along with the immunoreactivity of each intratumoral protein marker. The multivariate Cox model was selected using backward stepwise selection to eliminate non-significant variables at p < 0.1. Hazard ratios (HRs) were calculated, along with their associated 95% confidence intervals (CIs). Statistical analyses were performed using SAS statistical software (version 9.3) and R (version 3.3.1) and all reported p-values are two-sided.

3. Results

3.1. Patient Characteristics

A total of 34 patients with advanced BTC were enrolled during the study period (Table 1). Sixteen (47%) of these patients were diagnosed with GB cancer, followed by 10 (29%) with intrahepatic and eight (24%) with extrahepatic CCA. Among them, 10 patients (extrahepatic CCA: 7; GB cancer: 2, intrahepatic CCA: 1) were recurrent cases, and the median time to recurrence after surgery was 9.4 months (range, 1.4–20.2 months). Assessments of the degree of differentiation showed that two (6%) tumors were well-differentiated, 16 (47%) were moderately differentiated, and 13 (38%) were poorly differentiated adenocarcinomas. Twenty-four patients (71%) had metastatic disease, with the most common metastatic sites being distant lymph nodes in 20 patients and the liver in 16 patients.
Table 1. Clinicopathological characteristics and univariate analysis of survival outcomes.

| Variables                              | N (%) | Univariate (Overall Survival) | Univariate (Progression-Free Survival) |
|----------------------------------------|-------|-------------------------------|----------------------------------------|
| Age, median (range)                    | 65.5 (45–81) | 31 1.00 (0.96–1.05) 0.859 | 31 1.01 (0.96–1.06) 0.653 |
| Sex                                    |       |                               |                                        |
| Male                                   | 20 (58.8) | 19 0.78 (0.38–1.61) 0.498 | 20 1.06 (0.29–1.33) 0.215 |
| Female                                 | 14 (41.2) | 12 0.78 (0.38–1.61) 0.498 | 11 0.62 (0.29–1.33) 0.215 |
| Primary tumor site                     |       |                               |                                        |
| Extrahepatic                           | 8 (23.5) | 8 1.00 (0.96–1.05) 0.859 | 7 1.00 (0.96–1.05) 0.859 |
| Gallbladder                            | 16 (47.1) | 13 0.78 (0.32–1.89) 0.574 | 15 1.10 (0.42–2.85) 0.852 |
| Intrahepatic                           | 10 (29.4) | 10 1.21 (0.47–3.11) 0.690 | 19 1.56 (0.55–1.46) 0.404 |
| Pathological differentiation           |       |                               |                                        |
| Well                                   | 2 (6.5) | 2 1.00 (0.96–1.05) 0.859 | 2 1.00 (0.96–1.05) 0.859 |
| Moderately                             | 16 (51.6) | 14 0.74 (0.16–3.34) 0.691 | 14 0.63 (0.14–2.94) 0.556 |
| Poorly                                 | 13 (41.9) | 12 0.46 (0.10–2.13) 0.317 | 12 0.63 (0.14–2.94) 0.556 |
| Stage                                  |       |                               |                                        |
| Metastatic disease                     | 24 (70.6) | 21 1.00 (0.96–1.05) 0.859 | 22 1.00 (0.96–1.05) 0.859 |
| Recurrent disease                      | 10 (29.4) | 10 0.87 (0.40–1.85) 0.708 | 9 0.62 (0.27–1.41) 0.252 |
| Metastatic sites                       |       |                               |                                        |
| Liver metastasis                       | 16 (47.1) | 14 1.00 (0.96–1.05) 0.859 | 16 1.28 (0.62–2.64) 0.502 |
| Lung metastasis                        | 5 (14.7) | 5 1.96 (0.74–5.20) 0.179 | 5 5.95 (1.92–18.5) 0.002 |
| Peritoneal seeding                     | 6 (17.7) | 6 3.07 (1.21–7.82) 0.018 | 6 2.53 (0.99–6.49) 0.054 |
| Lymph node metastasis                  | 20 (58.8) | 18 0.97 (0.47–1.99) 0.929 | 17 0.80 (0.39–1.64) 0.538 |
| Number of metastatic sites             | 31     | 0.97 (0.47–1.99) 0.929 | 31 0.80 (0.39–1.64) 0.538 |
| 1                                      | 19 (55.9) | 17 3.07 (1.21–7.82) 0.018 | 16 3.07 (1.21–7.82) 0.018 |
| 2                                      | 12 (35.3) | 11 2.00 (0.84–4.52) 0.119 | 12 2.00 (0.84–4.52) 0.119 |
| 3 or more                              | 3 (8.8) | 3 2.00 (0.84–4.52) 0.119 | 3 2.00 (0.84–4.52) 0.119 |
| IHC expression                         |       |                               |                                        |
| hENT1                                  | 25 (73.5) | 23 1.95 (0.84–4.52) 0.119 | 23 1.73 (0.72–4.13) 0.219 |
| DCK                                    | 11 (32.4) | 11 1.00 (0.48–2.10) 0.997 | 11 1.16 (0.55–2.47) 0.697 |
| CDA                                    | 12 (36.4) | 12 1.39 (0.66–2.94) 0.390 | 11 1.00 (0.46–2.18) 0.988 |
| RRM1                                   | 10 (30.3) | 10 2.00 (1.03–5.14) 0.043 | 9 1.68 (0.75–3.77) 0.207 |

HR, hazard ratio; CI, confidence interval; hENT1, human Equilibrative Nucleoside Transporter; DCK, deoxycytidine kinase; CDA, deoxycytidine deaminase; RRM1, Ribonucleotide Reductase M1.

3.2. Immunohistochemistry Staining of Biomarker Expression

Representative examples of positive immunohistochemical labeling profiles are shown in Figure 1. Cellular staining was localized to the cytoplasm for hENT1, DCK, and RRM1, the nucleus and cytoplasm for CDA. Immunohistochemical labeling was defined as positive when hENT1, DCK, and CDA were 1+ or higher, and RRM1 was 2+ or higher. Of the
34 patients, hENT1-positive was in 25 (73.5%), DCK-positive in 11 (32.4%), CDA-positive in 12 (36.4%), and RRM1-positive in 10 (30.3%). Negative examples are also presented in Figure S1. There were no significant differences in clinicopathological characteristics based on the positivity of each biomarker, except that GB cancers were frequently observed in hENT1-positive and metastatic disease was common in DCK-positive (Table S1).

![Immunohistochemical analysis of the intratumoral expression of proteins associated with gemcitabine transport and metabolism in patients with biliary tract cancers.](image)

**Figure 1.** Immunohistochemical analysis of the intratumoral expression of proteins associated with gemcitabine transport and metabolism in patients with biliary tract cancers. (A) hENT1 in gallbladder (GB) cancer, (B) DCK in intrahepatic cholangiocarcinoma, (C) CDA in GB cancer, (D) RRM1 in GB cancer.

### 3.3. Treatment Outcomes and Intratumoral Biomarker Expression

During the median follow-up of 34.2 months (95% CI, 5.2–63.2 months), 31 (91%) of the 34 patients experienced disease progression and died. Patients received a median of 5 cycles (range, 1–18 cycles) of chemotherapy. Three patients (8.8%) showed partial responses to GP treatment and the disease control rate (DCR) was 58.8%. Median OS and PFS were 7.5 months (95% CI, 5.4–9.6 months) and 4.4 months (95% CI, 3.4–5.4 months), respectively.

The association between chemotherapy effectiveness and biomarker expression was evaluated in Table 2. Expression of hENT1, DCK, CDA, and RRM1 was not significantly associated with response to GP chemotherapy.

| Variables | Chemotherapy Response | p Value |
|-----------|-----------------------|---------|
|           | PR + SD (%) | PD (%) |       |
| hENT1     |             |         |       |
| (−)       | 4 (44.4)    | 5 (55.6)| 1     |
| (+)       | 10 (40)     | 15 (60) |        |
| DCK       |             |         | 0.257 |
| (−)       | 10 (43.5)   | 13 (56.5)|      |
| (+)       | 4 (36.4)    | 7 (63.6) |        |
| CDA       |             |         | 1     |
| (−)       | 9 (42.9)    | 12 (57.1)|      |
| (+)       | 5 (41.7)    | 7 (58.3) |        |
| RRM1      |             |         | 0.257 |
| (−)       | 8 (34.8)    | 15 (65.2)|      |
| (+)       | 6 (60)      | 4 (40)  |        |

PR, partial response; SD, stable disease; PD, progression disease; HR, hazard ratio; CI, confidence interval; hENT1, human Equilibrative Nucleoside Transporter; DCK, deoxycytidine kinase; CDA, deoxycytidine deaminase; RRM1, Ribonucleotide Reductase M1.
Survival analysis was performed according to each biomarker. There was no significant difference in survival between positive and negative in hENT1, DCK, and CDA. Median PFS was longer in RRM1-negative (4.4 months; 95% CI, 3.0–5.8 months) than in RRM1-positive (2.1 months; 95% CI, 0–4.3 months) patients (Figure 2). However, this trend did not reach statistical significance. On the other hand, median OS was significantly longer in RRM1-negative than in RRM1-positive (9.9 months vs. 5.9 months, $p = 0.037$) (Figure 3).

**Figure 2.** Kaplan–Meier analysis of the relationships of intratumoral expression of biomarkers with progression-free survival in patients with biliary tract cancers. (A) hENT1, (B) DCK, (C) CDA, (D) RRM1. hENT1, human equilibrative nucleoside transporter 1; DCK, deoxycytidine kinase; CDA, Cytidine deaminase; RRM1, ribonucleotide reductase subunit 1.

**Figure 3.** Kaplan–Meier analysis of the relationships of intratumoral expression of biomarkers with overall survival in patients with biliary tract cancers. (A) hENT1, (B) DCK, (C) CDA, (D) RRM1. hENT1, human equilibrative nucleoside transporter 1; DCK, deoxycytidine kinase; CDA, Cytidine deaminase; RRM1, ribonucleotide reductase subunit 1.
The prognostic effect of intratumoral protein markers on survival in patients with BTC was assessed by Cox proportional hazards modeling based on the expression of CDA, hENT1, DCK, and RRM1. Univariate analyses showed that the number of metastatic sites and lung metastasis were significantly associated with PFS (Table 1). Further, the number of metastatic sites and peritoneal seeding, and RRM1 expression were significantly associated with OS (Tables 1 and 2). Multivariate analyses adjusted by variables with $p < 0.1$ on univariate analyses were performed according to each biomarker. Potential confounding factors (number of metastatic sites and lung metastasis or peritoneal seeding) could not be included simultaneously in a multivariate analysis, so the number of metastatic sites was separately added to the multivariate analysis for each biomarker. Multivariate-adjusted hazard ratios of each biomarker for overall survival were presented in Table 3 and Table S3. RRM1 positivity was significantly associated with poorer OS, whereas there was a nonstatistically significant association with PFS (Table S2). Other biomarkers were not associated with survival outcomes.

### Table 3. Multivariate analysis for overall survival in RRM1 expression including peritoneal seeding or the number of metastatic sites.

|                      | HR (95%CI)   | $p$ Value |
|----------------------|-------------|-----------|
| Model 1 including peritoneal seeding |             |           |
| RRM1 expression      | 3.33 (1.37–8.07) | 0.008     |
| Peritoneal seeding   | 4.99 (1.76–14.2) | 0.003     |
| Model 2 including number of metastatic sites |             |           |
| RRM1 expression      | 3.44 (1.40–8.45) | 0.007     |
| Number of metastatic sites | 2.30 (1.30–4.05) | 0.004     |

4. Discussion

The prognosis of patients with BTC remains poor, with GP chemotherapy being the main treatment option for patients with unresectable BTC [3]. No definitive prognostic biomarkers for survival have been available in the clinical setting for patients with advanced BTC [21]. Because of its wide applicability and cost-effectiveness, IHC is frequently used to identify biomarkers associated with survival [17]. The present study evaluated the prognostic ability of intratumoral expression of hENT1, DCK, CDA and RRM1 to assess survival in patients with advanced BTC treated with GP chemotherapy. OS was significantly longer in patients with RRM1-negative than RRM1-positive tumors, and the result demonstrated that the expression of RRM1 was an independent predictor for survival in patients treated with GP for metastatic or recurrent BTC.

The prognostic or predictive activity of RRM1 expression has been evaluated preclinically and clinically in various types of cancer [22]. For example, several retrospective studies have evaluated the association between RRM1 expression and survival outcomes in patients with BTC. Although two studies found that low RRM1 expression was significantly associated with prolonged OS [23,24], two other studies found no significant differences between patients with high and low RRM1 expression [15,25]. The present study found that RRM1-negative was significantly associated with prolonged OS. Although the small number of the study population was limited in showing the survival difference with sufficient power, there were no significant differences in baseline characteristics between RRM1-positive and negative groups. The prognostic significance of RRM1 was also made both in univariate and multivariate analysis. RRM1 is a crucial enzyme catalyzing the conversion of ribonucleoside diphosphates to deoxyribonucleoside diphosphates, which are utilized for DNA synthesis and repair [22,26]. Gemcitabine, an analogue of deoxycytidine, and its metabolite inhibit RRM1 activity by binding to one of its subunits [22]. In this regard, RRM1 abundance might reduce the cytotoxic effect of gemcitabine on DNA synthesis and affect poor survival outcomes in advanced BTC patients. Previous studies reported RRM1 as a potential predictive biomarker of gemcitabine in CCA, the expression...
of RRM1 in this study, however, did not show an association with chemotherapy response, limiting its use as a predictive biomarker of GP chemotherapy efficacy [24,27].

The most frequently studied IHC biomarkers in patients with BTC are hENT1, RRM1 and ERCC1 [17]. High hENT1 expression has been shown to be a biomarker of prolonged patient survival in patients with unresectable BTC who were treated with gemcitabine monotherapy or a gemcitabine-based regimen other than GP [14,15,28]. The current study, however, found that hENT1 was not associated with OS and PFS. DCK expression, which is significantly associated with PFS in our previous prospective study including patients with resected BTC, was not associated with survival outcomes in this study [19]. Gemcitabine is transported into the cell through the hENT1 and is activated by DCK or catabolized by CDA. Phosphorylated gemcitabine, the active form of gemcitabine, is incorporated into DNA to exhibit a cytotoxic effect and further inhibits DNA synthesis by suppressing RRM1. In considering these mechanisms, we assumed that the direct cytotoxic effect of gemcitabine appears after the phosphorylation, and therefore the expression of RRM1 related to activated gemcitabine would reflect survival outcomes in patients treated with GP chemotherapy compared to other biomarkers.

The present study had several limitations. First, the sample size was small, which is the most important consideration in interpreting the results of this study. BTC is a rare disease, and the rarity of this disease has been an unresolved constraint on patient collection. As BTCs are a highly heterogeneous group of GB cancer, intrahepatic and extrahepatic CCA, it also needs to be counted. In our study, a relatively high proportion of patients diagnosed with GB cancer (47%) were enrolled. Therefore, a further multicenter design study that can adequately include sufficient numbers to ensure statistical representation is warranted. To the best of our knowledge, few studies have concurrently analyzed three or more biomarkers in sufficient samples of unresectable BTCs. Concurrent analysis of biomarkers could be a benefit for interpreting results in consideration of interactions between each biomarker. Furthermore, most studies evaluating the prognostic efficacy of IHC markers were retrospective in design; for example, a recent systemic review and meta-analysis of 26 articles included only two phase-II studies [17,19,29]. Therefore, the prospective nature of the present study would be overcome some of the limitations of retrospective studies, such as collecting tissue samples and clinical data. Finally, the absence of an optimal IHC protocol is a significant hurdle in investigating and comparing the effectiveness of biomarker expressions. Previous studies assessed the expression level of the biomarker at the cut-off for positivity with the percentage of staining tumor cells over 50% or H-score of 6 points, which was calculated as the product of the staining intensity and the percentage of positive cells [17]. On the other hand, our immunostaining intensity and positivity were determined by the most strongly stained tumor cell. Consequently, positivity could be overestimated and contribute to the inconsistency with previously reported results. However, our approach to the staining intensity would have the advantage of being simplified and can be evaluated quickly. Large-scale well-defined prospective research is needed to develop and standardize IHC protocol and validate the utility of biomarkers in clinical practice.

5. Conclusions

In conclusion, the present study found that RRM1 expression was significantly associated with OS in patients with unresectable BTC who were treated with GP chemotherapy. RRM1 expression may therefore be a potential prognostic biomarker for advanced BTC patients. A large-scale, prospective validation of this biomarker is warranted.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/jcm10204652/s1, Figure S1: Representative examples of negative immunohistochemical labeling profiles. (A) hENT1 in extrahepatic cholangiocarcinoma (eCCA) (B) DCK in gallbladder cancer, (C) CDA in eCCA, (D) Faint staining of RRM1 in eCCA; Table S1: Baseline characteristics according to each biomarker expression; Table S2: Multivariate analysis for progression free survival in each biomarker including peritoneal seeding and lung metastasis or the number of metastatic sites; Table S3: Multivariate analysis for overall survival in each biomarker including peritoneal seeding or number of metastatic sites.

Author Contributions: S.M.W. conceived the study, and performed data analysis and manuscript preparation. J.W.C. and B.L. performed data analysis and manuscript preparation. E.K.H., N.H., and W.S.P. participated in data collection, analysis and manuscript preparation. E.Y.P. performed data analysis. S.S.H., S.-J.P., and T.H.K. collected data and edited manuscript. W.J.L. collected data and designed the study. All authors have read and agreed to the published version of the manuscript.

Funding: The present study was supported by grants from the National Cancer Center, Korea (Grant numbers 1610040, 1910190, 1810864).

Institutional Review Board Statement: The study protocol was approved by the Institutional Review Board of the National Cancer Center, Korea (IRB No. NCC2015-0113) and was conducted in accordance with the provisions of the Declaration of Helsinki.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgments: The authors thank Young Hwa Kang, Jihye Yu and Mee Young Lee for their help in collecting patient specimens and clinical data.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. De Groen, P.C.; Gores, G.J.; LaRusso, N.F.; Gunderson, L.L.; Nagorney, D.M. Biliary Tract Cancers. N. Engl. J. Med. 1999, 341, 1368–1378. [CrossRef] [PubMed]
2. Park, J.O.; Oh, D.-Y.; Hsu, C.; Chen, J.-S.; Chen, L.-T.; Orlando, M.; Kim, J.S.; Lim, H.Y. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res. Treat. 2015, 47, 343–361. [CrossRef] [PubMed]
3. Tariq, N.-U.-A.; McNamara, M.G.; Valle, J.W. Biliary tract cancers: Current knowledge, clinical candidates and future challenges. Cancer Manag. Res. 2019, 11, 2623–2642. [CrossRef] [PubMed]
4. André, T.; Reyes-Vidal, J.M.; Fartoux, L.; Ross, P.; Leslie, M.; Rosmorduc, O.; Clemens, M.R.; Louvet, C.; Perez, N.; Mehmud, F.; et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: A phase II study. Br. J. Cancer 2008, 99, 862–867. [CrossRef] [PubMed]
5. Knox, J.J.; Hedley, D.; Oza, A.; Feld, R.; Siu, L.L.; Chen, E.; Nemmatollahi, M.; Pond, G.R.; Zhang, J.; Moore, M.J. Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial. J. Clin. Oncol. 2005, 23, 2323–2338. [CrossRef]
6. Okusaka, T.; Ishii, H.; Funakoshi, A.; Yamao, K.; Ohkawa, S.; Saito, S.; Saito, H.; Tsuyuguchi, T. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother. Pharmacol. 2006, 57, 647–653. [CrossRef]
7. Valle, J.; Wasan, H.; Palmer, D.H.; Cunningham, D.; Anthoney, A.; Maraveyas, A.; Madhusudan, S.; Iveson, T.; Hughes, S.; Pereira, S.P.; et al. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. N. Engl. J. Med. 2010, 362, 1273–1281. [CrossRef] [PubMed]
8. Voutsadakis, I.A. Molecular predictors of gemcitabine response in pancreatic cancer. World J. Gastrointest. Oncol. 2011, 3, 153–164. [CrossRef]
9. Amrutkar, M.; Gladhaug, I.P. Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers 2017, 9, 157. [CrossRef]
10. Lane, J.; Martin, T.A.; McGuigan, C.; Mason, M.D.; Jiang, W. The differential expression of hCNT1 and hENT1 in breast cancer and the possible impact on breast cancer therapy. J. Exp. Ther. Oncol. 2010, 8, 203–210. [CrossRef]
11. Achiwa, H.; Oguri, T.; Sato, S.; Maeda, H.; Niimi, T.; Ueda, R. Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxyctydine kinase in non-small cell lung cancer. Cancer Sci. 2004, 95, 753–757. [CrossRef]
12. Bepler, G.; Kusmartseva, I.; Sharma, S.; Gautam, A.; Cantor, A.; Sharma, A.; Simon, G. RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non–Small-Cell Lung Cancer. J. Clin. Oncol. 2006, 24, 4731–4737. [CrossRef] [PubMed]
13. Tibaldi, C.; on behalf of The Italian Oncological Group of Clinical Research (GOIRC); Camerini, A.; Tiseo, M.; Mazzoni, F.; Barbieri, F.; Vittimberga, L; Brighenti, M.; Boni, L.; Baldini, E.; et al. Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: A prospective validation study. *Br. J. Cancer* 2018, 119, 1326–1331. [CrossRef] [PubMed]

14. Borbath, I.; Verbrugghe, L.; Lai, R.; Gigot, J.; Humblet, Y.; Pissieuxaux, H.; Sempoux, C. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. *Eur. J. Cancer* 2012, 48, 990–996. [CrossRef]

15. Deng, T.; Pan, H.; Han, R.; Huang, D.; Li, H.; Zhou, L.; Wang, X.; Bai, M.; Li, X.; Liu, R.; et al. Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer. *Int. J. Clin. Exp. Med.* 2014, 7, 5041–5049.

16. Kim, J.; Kim, H.; Lee, J.-C.; Kim, J.W.; Paik, W.H.; Lee, S.H.; Hwang, J.-H.; Ryu, J.K.; Kim, Y.-T. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer. *PLoS ONE* 2018, 13, e0209104. [CrossRef] [PubMed]

17. Belkouz, A.; Labeur, T.A.; Dierks, J.; Dijk, F.; van Oijen, M.G.; Verheij, J.; van Gulik, T.M.; van de Vijver, M.J.; Wilmink, H.; Punt, C.J.; et al. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis. *Crit. Rev. Oncol. Hematol.* 2019, 141, 82–94. [CrossRef]

18. Yoon, K.-A.; Woo, S.M.; Hong, E.K.; Jung, M.K.; Park, W.S.; Bae, K.; Han, S.-S.; Kim, T.H.; Koh, Y.H.; Park, S.-J.; et al. Cytidine Deaminase as a Molecular Predictive Response in Patients with Biliary Tract Cancer. *Oncology* 2015, 89, 345–350. [CrossRef]

19. Woo, S.M.; Yoon, K.-A.; Hong, E.K.; Park, W.S.; Han, S.-S.; Park, S.-J.; Joo, J.; Park, E.Y.; Lee, J.H.; Kim, Y.-H.; et al. DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: Results from a phase II study. *Oncotarget* 2017, 8, 81394–81404. [CrossRef] [PubMed]

20. Shuster, J.J. Median follow-up in clinical trials. *J. Clin. Oncol.* 1991, 9, 191–192. [CrossRef]

21. Macias, R.I.R.; Kornek, M.; Rodrigues, P.M.; Paiva, N.A.; Castro, R.E.; Urban, S.; Pereira, S.P.; Cadamuro, M.; Rupp, C.; Loosen, J.; et al. Diagnostic and prognostic biomarkers in cholangiocarcinoma. *Liver Int.* 2019, 39, 108–122. [CrossRef]

22. Jordheim, L.P.; Seve, P.; Tredan, O.; Dumontet, C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. *Lancet Oncol.* 2011, 12, 693–702. [CrossRef]

23. Miyazaki, K.; Nakamura, J.; Kohya, N.; Kai, K.; Ohtaka, K.; Hashiguchi, K.; Hiraki, M.; Kitajima, Y.; Tokunaga, O.; Noshiro, H. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma. *Int. J. Oncol.* 2010, 37, 845–852. [CrossRef]

24. Sasaki, H.; Murakami, Y.; Uemura, K.; Sudo, T.; Hashimoto, Y.; Kondo, N.; Sueda, T. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. *Br. J. Cancer* 2014, 111, 1275–1284. [CrossRef] [PubMed]

25. Murata, A.; Amano, R.; Yamada, N.; Kimura, K.; Yashiro, M.; Nakata, B.; Hirakawa, K. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone. *World J. Surg. Oncol.* 2013, 11, 1–117. [CrossRef] [PubMed]

26. Gong, W.; Zhang, X.; Wu, J.; Chen, L.; Li, L.; Sun, J.; Lv, Y.; Wei, X.; Du, Y.; Jin, H.; et al. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: A meta-analysis. *Lung Cancer* 2012, 75, 374–380. [CrossRef] [PubMed]

27. Wakai, T.; Shirai, Y.; Sakata, J.; Takamura, M.; Matsuda, Y.; Korita, P.V.; Muneoka, K.; Sasaki, M.; Ajioka, Y.; Hatakeyama, K. Ribonucleotide Reductase M1 Expression in Intrahepatic Cholangiocarcinoma. *Hepatogastroenterology* 2011, 58, 1659–1663. [CrossRef]

28. Santinii, D.; Schiavon, G.; Vincenzi, B.; Cass, C.E.; Vasile, E.; Mananza, A.D.; Catalano, V.; Baldi, G.G.; Lai, R.; Rizzo, S.; et al. Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC). *Curr. Cancer Drug Targets* 2011, 11, 123–129. [CrossRef]

29. Chiang, N.-J.; Hsu, C.; Chen, J.-S.; Tsou, H.-H.; Shen, Y.-Y.; Chao, Y.; Chen, M.-H.; Yeh, T.-S.; Shan, Y.-S.; Huang, S.-F.; et al. Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. *Sci. Rep.* 2016, 6, 25369. [CrossRef]